SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-271116
Filing Date
2024-12-05
Accepted
2024-12-05 07:52:59
Documents
15
Period of Report
2024-12-05
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d809707d8k.htm   iXBRL 8-K 36174
2 EX-99.1 d809707dex991.htm EX-99.1 15057
6 GRAPHIC g809707g1204213130383.jpg GRAPHIC 6894
  Complete submission text file 0001193125-24-271116.txt   197007

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cgon-20241205.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cgon-20241205_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cgon-20241205_pre.xml EX-101.PRE 11725
17 EXTRACTED XBRL INSTANCE DOCUMENT d809707d8k_htm.xml XML 3768
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

IRS No.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41925 | Film No.: 241527855
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)